



Dr. Reddy's Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN : L85195TG1984PLC004507

Tel : +91 40 4900 2900
Fax : +91 40 4900 2999
Email : mail@drreddys.com
www.drreddys.com

January 11, 2021

Corporate Relationship Department
BSE Limited
Dalal Street, Fort
Mumbai – 400 001
Fax Nos.: 022-22723121 / 22723719 /
22722037 / 22722039

National Stock Exchange of India Ltd.
“Exchange Plaza”
Bandra-Kurla Complex, Bandra (East),
Mumbai – 400 051
Fax Nos.: 022-26598120/ 26598237/
26598238

Scrip Code: 500124

Scrip Code: DRREDDY-EQ

Dear Sirs,

Sub: Press Release

Please find enclosed a Press Release on “**Dr. Reddy's Laboratories to present at the 39th Annual J.P. Morgan Healthcare Conference.**”

This is for your information.

With regards,

SANDEEP
PODDAR

Sandeep Poddar
Company Secretary

Encl: As above

CC:- New York Stock Exchange Inc.(Stock Code :RDY)
NSE IFSC Ltd

Digitally signed by SANDEEP PODDAR
DN: cn=Dr. Reddy's Laboratories Ltd.,
ou=Dr. Reddy's Laboratories Ltd.,
o=Dr. Reddy's Laboratories Ltd.,
c=IN,
email=mail@drreddys.com,
serialNumber=8185d5106e0d0196014ae660c09b
ac334f5ebc1a1790e158f29af332f208cac,
cn=SANDEEP PODDAR
Date: 2021.01.11 19:17:40 +05'30'

DR. REDDY'S LABORATORIES LTD.

8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500034. Telangana, India.

CONTACT**INVESTOR RELATIONS**

AMIT AGARWAL
amita@drreddys.com
(PH: +91-40-49002135)

MEDIA RELATIONS

APARNA TEKURI
aparnatekuri@drreddys.com
(PH: +91-40- 49002446)

Dr. Reddy's Laboratories to present at the 39th Annual J.P. Morgan Healthcare Conference

Hyderabad, India, January 11, 2021

For Immediate Release

Hyderabad, India and Princeton, NJ, USA. January 11th, 2021 — Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) announced that the Company will be presenting at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, 13th January, 2021.

Erez Israeli, company's Chief Executive Officer will present at the Fireside Chat session at 11:00 AM EST [9:30 PM IST].

Weblink to join and listen to the fire side chat is given below:

https://jpmorgan.metameetings.net/events/healthcare21/sessions/35274-dr-reddy-s-laboratories-ltd/webcast?gpu_only=true&kiosk=true

About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2020. The company assumes no obligation to update any information contained herein."

**SANDEEP
PODDAR**

Digitally signed by SANDEEP PODDAR
DN: cn=IN, o=Personal,
pseudoym=5bae504542ac09e3878c9d91f0db36d548a0
2.5.4.20-bfda99c392e4dc357a2e12970b9505d5d51634ab609
953e786cc73ae7468994, postalCode=500084,
st=TELANGANA,
serialNumber=185d5106a0d6190f1aee60cc09bac334f5ebc
1a1790e158f2b433e208ac, cn=SANDEEP PODDAR
Date: 2021.01.11 19:18:43 +05'30'